FindTrial
Sign In

Multiple center's clinical treatment of systemic onset juvenile idiopathic arthritis with tocilizumab

Multiple center's clinical treatment of systemic onset juvenile idiopathic arthritis with tocilizumab

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR-INR-17011829
Enrollment
Unknown
Registered
2017-07-02
Start date
2017-08-01
Completion date
Unknown
Last updated
2017-07-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Systemic onset juvenile idiopathic arthritis

Interventions

Case:Tocilizumab
Control:Conventional Treatment

Sponsors

Shenzhen Children's Hospital
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1. Pass the diagnosis standard of JIA from ILAR; 2. diagnosed as severe active period; 3. To be able to treated with appropriate glucocorticoid, MTX and/or NSAIDs, no other DMARDs allowed.

Exclusion criteria

Exclusion criteria: 1) no latent diseases such as TB, HBV oe EBV; 2) no hypersensitivity to Tocilizumab or other accessories; 3) no macrophage activiation syndrome; 4) reject to sign the infromed consent; 5) participate in other clinical experiments simultaneously.

Design outcomes

Primary

MeasureTime frame
IL-1;IL-6;IL-18;TNF-a;S100A8;S100A9;Index of joint pain;Index of joints swelling;Reheating time;ESR;CRP;SF;—

Countries

China

Contacts

Public ContactYang Jun

Shenzhen Children's Hospital

rogasansz@163.com+86 18938690366

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026